9月8日 - ** Intellia Therapeutics（NTLA.O）股价在盘前交易中上涨6.4%，至13.55美元
** 该公司表示，美国食品药品监督管理局（FDA）已受理其申请，寻求批准将lonvoguran ziclumeran（简称lonvo-z）作为遗传性血管性水肿（HAE）的实验性治疗药物，并授予其优先审评资格
** 遗传性血管性水肿（HAE）是一种罕见的遗传性疾病，会引发反复发作且可能危及生命的肿胀发作
** 该监管机构将该疗法的审评目标日期定为明年3月10日
** 若获批准，lonvo-z将成为首个上市的基于CRISPR技术的体内基因编辑疗法，也是首个针对HAE的单次治疗方案——NTLA
** 该申请得到了晚期临床试验数据 (link) 的支持，数据显示在第5周至第28周的主要评估期间，与安慰剂相比，单次剂量的lonvo-z将平均每月发作次数减少了87%
** NTLA表示，FDA目前暂无计划召开咨询委员会会议来讨论该申请
** 截至上一交易日收盘，该股年内累计跌幅达41.7%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.